Explore ViiV Healthcare

I am a

... looking for

US News

News
Company Statements

ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1

06 Aug 2020
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP

07 Jul 2020
ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life

04 Jul 2020
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices

04 Jul 2020
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)

02 Jul 2020
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available

02 Jul 2020
ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic

30 Jun 2020
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV

12 Jun 2020
National AIDS Memorial and ViiV Healthcare Create Mary Bowman Arts in Activism Award to Support Young Artist-Activists Committed to the Fight Against HIV/AIDS

26 May 2020
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

18 May 2020
ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic

27 Apr 2020
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting HIV-treatment regimen in adults living with HIV-1

09 Mar 2020
ViiV Healthcare presents positive, 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

09 Mar 2020
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership

09 Mar 2020
ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV

02 Mar 2020
ViiV Healthcare submits regulatory application to the European Medicines Agency for investigational fostemsavir, a first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

10 Jan 2020

ViiV Healthcare COVID-19 Community Emergency Response Fund

27 Apr 2020
ViiV Healthcare ranks #1 company in the PatientView ‘Corporate Reputation of Pharma – from the Patient Perspective 2019 – 2020’ survey

21 Apr 2020
ViiV Healthcare’s commitment to support AIDS2020 and key conferences during COVID-19 outbreak

30 Mar 2020
COVID-19 Guidance to Investigators

27 Mar 2020
Our Response to COVID-19

16 Mar 2020

Website images are not intended to imply that the models pictured have HIV.

©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.

Connect with us